XML 38 R18.htm IDEA: XBRL DOCUMENT v3.22.1

Revenues (Tables)

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three months ended March 31, 2022 and 2021:

									Three months ended March 31,
															2022						2021
Products:
Kristalose															$	3,945,097					$	2,994,378
Sancuso															3,397,209						—
Vibativ															2,501,434						5,052,243
Caldolor															959,634						1,539,496
Vaprisol															(117,000)						1,134,264
Acetadote															111,090						117,191
Omeclamox-Pak															22,737						(450,263)
RediTrex															59,226						(32,252)
Other revenue															295,618						182,102
Total net revenues															$	11,175,045					$	10,537,159

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration